Komori
P

Pharma Foods International Co.,Ltd.

2929FoodMicro cap
684JPY-4.1%
★ Watch (sign-up required)
Price history
¥684Latest-69.9%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

Pharma Foods International Co.,Ltd. is a corporate group built around three core business categories. Its B2B business researches, develops and manufactures functional ingredients, health foods and pharmaceuticals, supplying food and pharmaceutical manufacturers and distributors in Japan and overseas. Its B2C business sells supplements, quasi-drugs and cosmetics containing its proprietary ingredients through direct mail and retail stores. Its biomedical business conducts drug discovery and research support, advancing R&D on antibody and peptide pharmaceuticals based on ALAgene technology. The business structure comprises Pharma Foods International Co.,Ltd., 7 consolidated subsidiaries and 1 equity-method affiliate. Major consolidated subsidiaries include Pharma Foods Communication, Future Labo, Medi Labo and Meiji Pharmaceutical.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 18
PBR
1.97How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
-10.5%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥20bnShare price × number of shares. The value of the entire company.
Equity ratio
28.9%The proportion of assets funded by money that does not have to be repaid.
Operating margin
-2.9%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
-2.6%The average annual growth in sales over the past three years.
Forward P/E
13.26Forward P/E based on estimated earnings for the next fiscal year.
What to watch next
中期経営計画2029「1Kプロジェクト - SPRING戦略 -」の具体施策（投資・収益目標・KPI）進捗開示
今後数四半期〜（計画の実行フェーズの開示次第）Impact MediumLikelihood Medium
GABAの米国FDA GRAS認証取得（準備最終段階→取得完了）
2026年度内〜次年度（取得時点は未確定）Impact HighLikelihood Medium
卵殻膜ovoveilの量産化投資（約50億円超/新工場・ライン追加含む）に関する進捗：稼働、顧客採用、販売立ち上がり
2025〜2027年（投資計画の実行進捗に依存）Impact HighLikelihood Medium
明治薬品（富山工場）新工場計画：着工（2026年7月）〜能力増強の進捗
2026年7月着工、完了は2028年7月（計画通りなら）Impact MediumLikelihood Medium
マリン・プロフーズ子会社化（2026年10月6日決議・取得対価5,030百万円）後の業績寄与（のれん/償却負担含む）と統合効果
2027年以降（連結反映後の四半期）Impact MediumLikelihood Low
What to watch next
Loading
Who owns itTop holders total 38.3%
Listed holders 38.3%Everyone else 61.7%
The Master Trust Bank of Japan, Ltd. (Trust Account)8.35%
Kim Mu-jo (金 武祚)7.79%
株式会社PFホールディングス5.10%
ITOCHU Corporation5.00%
Masuda Kazuyuki (益田 和二行)2.65%
金 英一2.50%
ROHTO PHARMACEUTICAL CO.,LTD.2.07%
金 千尋1.75%
2 other listed holders3.07%
Who owns it
HolderOwnership (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)8.35
Kim Mu-jo (金 武祚)7.79
株式会社PFホールディングス5.10
ITOCHU Corporation5.00
Masuda Kazuyuki (益田 和二行)2.65
金 英一2.50
ROHTO PHARMACEUTICAL CO.,LTD.2.07
金 千尋1.75
2 other listed holders3.07
This company's documents
Filings
Timely disclosures
Threads